<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512096</url>
  </required_header>
  <id_info>
    <org_study_id>ID99-194</org_study_id>
    <nct_id>NCT00512096</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis</brief_title>
  <official_title>A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant
      chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell
      carcinoma of the penis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before treatment starts, participants will have a complete exam, including blood and urine
      tests. A CT scan of the abdomen and pelvis will be done. Participants will have a chest
      x-ray, bone scan, and an EKG (heart test). A special heart function test may also need to be
      done in some participants. If necessary a biopsy of enlarged lymph node(s) will be obtained
      prior to treatment.

      Blood tests will be repeated once a week during treatment. CT scans of the abdomen and pelvis
      and a Chest x-ray will be done after 2 treatments with Taxol, Ifosfamide, and Cisplatin.
      These will also be done before surgery.

      The drugs Taxol, Ifosfamide and Cisplatin will be given through a catheter (plastic tube)
      placed in a vein in the arm or under the collarbone. Taxol will be given over 3 hours the
      first day of the treatment cycle. To prevent an allergic reaction, before the Taxol is given,
      the participant will receive three drugs. These are Dexamethasone, Diphenhydramine, and
      either Cimetidine or Ranitidine.

      After Taxol, Ifosfamide will be given over 2 hours every day for the first three days of the
      treatment cycle. To prevent possible irritation of Ifosfamide to the bladder, participants
      will also receive Mesna through the plastic catheter. Mesna will be given both before and
      after Ifosfamide every day. Mesna is not chemotherapy. It is a medication to prevent side
      effects of Ifosfamide into the bladder.

      Every day for the first three days of the cycle, and after Ifosfamide is given, participants
      will also receive Cisplatin through the catheter at a steady rate over 2 hours, along with
      Mannitol and salt water to flush the kidneys. This treatment will be given in the hospital
      and will require staying in the hospital for 3-4 days. It will be repeated for a total of 4
      times; once every 21 days, if the participant has high enough numbers of white blood cells
      and platelets.

      Participants may be given injections of G-CSF under the skin once a day for up to 7 days
      (days 6-12 of the cycle) to bring the white cells up faster after the chemotherapy. This will
      also lower the risk of severe infections.

      After completing 4 treatments of chemotherapy, participants will have blood and urine tests,
      a chest x-ray to learn the response of the tumor to the chemotherapy. They will also have a
      CT scan of the abdomen and pelvis. Participants who have a response to the chemotherapy, or
      show no sign of new spread of the cancer to other parts of the body, will then have surgery.
      Surgery will be done to remove the tumor. The lymph nodes in the groin will be removed. The
      pelvic lymph nodes may also need to be removed. How much tissue is removed depends on how far
      the tumor has spread. The surgeons will explain the specifics of the surgery in a separate
      consent form.

      After completion of the treatment, physical exams, CT scans, chest x-rays, blood tests, and
      urine tests will be done every 3 months for 2 years. They will then be done every 6 months.
      These procedures can be done by a physician at M. D. Anderson or by the participant's own
      doctor. If the participant's doctor does it, the information will need to be forwarded to the
      doctors at M. D. Anderson. Participants will be expected to come to M. D. Anderson or to
      their respective participating urologist/medical oncologist at least once every 6 months for
      a check-up.

      This is an investigational study. The FDA has approved Taxol, Ifosfamide, Cisplatin, and
      Mesna. Up to 40 participants will take part in this study. All will be enrolled at M. D.
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pathologic Complete Remission (pCR)</measure>
    <time_frame>restaging with second and fourth 21-day cycles followed by surgery</time_frame>
    <description>Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Penile Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin + Ifosfamide + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>1200 mg/m^2 By Vein Over 2 Hours on Days 1-3</description>
    <arm_group_label>Cisplatin + Ifosfamide + Paclitaxel</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (Taxol)</intervention_name>
    <description>175 mg/m^2 By Vein Over 3 Hours on Day 1</description>
    <arm_group_label>Cisplatin + Ifosfamide + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m^2 By Vein Over 2 Hours on Days 1-3</description>
    <arm_group_label>Cisplatin + Ifosfamide + Paclitaxel</arm_group_label>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained from each patient prior to study entry.

          2. Age &gt;/= 14 years of age. Life expectancy greater than or equal to 6 months. PS &lt;/= 2
             (ECOG).

          3. Patients with histologically confirmed squamous cell carcinoma of the penis who
             present with clinical stage (T(subscript)xN(subscript)2-3M(subscript)0) disease based
             on the 1987-1992 TNM Staging System and meeting the additional clinicopathologic
             criteria as defined in the protocol (section 3.1).

          4. Patients must have adequate physiologic reserve as evidenced by: absolute neutrophil
             count (ANC) &gt;/= 1,500/mm3(superscript) and platelet count &gt;/= 100,000/mm3.
             Transaminases &lt;/= 2 times the upper limit of normal. Conjugated bilirubin &lt;/=
             1.5mg/dL. Creatinine clearance (either calculated or measured) of &gt;/= 40ml/minute.

          5. No evidence of active ischemia on the EKG and, for patients with significant prior
             coronary artery disease history, an ejection fraction of more than 40%. No evidence of
             severe conduction abnormalities on EKG.

        Exclusion Criteria:

          1. Patients with uncontrolled infection or CNS disease.

          2. Distant metastasis (TNM stage M1, i.e., lung, bone, other visceral sites, lymph node
             metastasis above the aortic bifurcation).

          3. Patients with clinically negative inguinal examinations or those with palpable
             adenopathy not meeting pathological or clinical criteria (i.e., minimal nodal
             metastasis or false positive inguinal examination).

          4. Prior systemic chemotherapy for penile carcinoma.

          5. Prior radiation therapy to inguinal or pelvic lymph nodes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance Pagliaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <results_reference>
    <citation>Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12.</citation>
    <PMID>20625118</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2007</study_first_posted>
  <results_first_submitted>November 3, 2010</results_first_submitted>
  <results_first_submitted_qc>November 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2010</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genitourinary</keyword>
  <keyword>Penile Cancer</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Extirpative Surgery</keyword>
  <keyword>TanyN2-3M0 Squamous Cell Carcinoma of the Penis</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Platinol-AQ</keyword>
  <keyword>Platinol</keyword>
  <keyword>CDDP</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Ifex</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period 17-AUG-99 to 15-OCT-08; all participants were recruited at MD Anderson Cancer Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cisplatin + Ifosfamide + Paclitaxel</title>
          <description>Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cisplatin + Ifosfamide + Paclitaxel</title>
          <description>Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="24" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pathologic Complete Remission (pCR)</title>
        <description>Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions.</description>
        <time_frame>restaging with second and fourth 21-day cycles followed by surgery</time_frame>
        <population>Participants who completed chemotherapy without progression then had surgical resection.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Ifosfamide + Paclitaxel</title>
            <description>Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologic Complete Remission (pCR)</title>
          <description>Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions.</description>
          <population>Participants who completed chemotherapy without progression then had surgical resection.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Nine years and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cisplatin + Ifosfamide + Paclitaxel</title>
          <description>Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocarcial ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>grade 3 only, no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>grade 4 only, no grade 3 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <description>grade 3, no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>grade 3 event, no grade 4</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <description>grade 3 events, no grade 4</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <description>grade 3 event, no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy motor</sub_title>
                <description>grade 3 event, no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <description>no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>central venous catheter related thrombosis</sub_title>
                <description>grade 3, no grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cherie A. Perez</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>caperez@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

